42Stockpicking

KYMR

Kymera Therapeutics IncExit· 100%· 6. jun. 2026
NASDAQ·Healthcare·USD

Henter pris…

Værdiansættelse (TTM)

P/Ei
EV/EBITDAi
P/Bi
3,8
57th %ile · 404p
P/Si
153,4
91st %ile · 356p
EV/Salesi
153,4
92nd %ile · 356p
Div yieldi

Kursudvikling

Pris

Data-readiness

10 års prishistorik er idealet for høj confidence.

Beregnet 10.6.2026strong
Prishistorik
5,8 år
Pris-dage
1457
Årsregnskaber
8
Peers
0/0
Valuation
3/6
Fundamentals
6/8
Datovindue
2020-08-21 til 2026-06-08

Blokkere

  • Raw confidence is below the 0.95 high-confidence guardrail.

Mangler før højere confidence

  • Mangler ca. 4,2 års prishistorik før ideal/full.
  • Kør compute-multiples for manglende valuation metrics.
  • Kør fetch-fundamentals-bulk/API fallback for manglende regnskabsmetrics.

Seneste assessment

KYMR vurderet 2026-06-10

Score
39.6%
Ikke high-confidence

Raw confidence is below the 0.95 high-confidence guardrail.

Sell watch placeholder

Stores exit-aware fields without issuing sell scores yet.

71%

Current drawdown: Future exit logic can use drawdown from recent high.

Trend break: Future exit logic can use moving-average trend breaks.

Valuation

Compares price paid with earnings, cash-generation proxies and sales.

33%

P/E: Reasonable P/E gets rewarded; very expensive or distressed multiples do not.

Earnings yield: Earnings yield is the inverse P/E lens.

Technicals

Checks trend, momentum and current damage from recent highs.

31%

6M momentum: Positive medium-term momentum confirms sponsorship.

Trend stack: Strong setup keeps price above MA50 and MA200 with MA50 above MA200.

Data quality

Checks whether the assessment has enough recent price, fundamental and valuation data.

87%

Price history depth: More than one trading year gives the technical pillar enough context.

Latest price freshness: Latest live or EOD price should be recent.

Macro/regime

Treats macro as context, not a standalone trading instruction.

46%

VIX: Normal volatility is supportive; panic or complacency is less clean.

10Y-2Y curve: Positive yield curve lowers recession stress.

Fundamentals

Scores growth, margins, capital efficiency, balance-sheet resilience and composite financial-health KPIs.

22%

Revenue growth 3Y: Sustained top-line growth supports durable compounding.

Gross margin: High gross margin gives room for reinvestment and downturns.

Peer/relative context

Adds relative context when sector peers have comparable data.

33%

Peer count: Peer context is only scored when comparable data exists.

P/E vs peers: P/E relative valuation needs both own multiple and peer median.

Insider activity

Net 90d (aktier)
-99.468
Net 90d (værdi)
-8.961.817 USD
Købere 90d
0
Cluster
DatoPersonRolleTypeAntalVærdiKilde
22.6.2026Booth Bruce▼ SALG-14.921-1.374.821 USDsec
22.6.2026Goodman NoahChief Business Officer◆ OPT.2.50052.625 USDsec
22.6.2026Goodman NoahChief Business Officer▼ SALG-2.500-247.500 USDsec
18.6.2026Booth Bruce▼ SALG-62.897-5.690.921 USDsec
17.6.2026Booth Bruce◆ OPT.11.741234.820 USDsec
17.6.2026Booth Bruce▼ SALG-11.741-1.056.455 USDsec
2.6.2026Jacobs Bruce N.Chief Financial Officer◆ OPT.12.65326.318 USDsec
27.5.2026Chadwick Jeremy GChief Operating Officer▼ SALG-3.679-299.850 USDsec
26.5.2026Chadwick Jeremy GChief Operating Officer▼ SALG-3.730-292.271 USDsec
19.5.2026Esposito Pamela◆ OPT.1.00031.200 USDsec
18.5.2026Jacobs Bruce N.Chief Financial Officer◆ OPT.15.00031.200 USDsec

Earnings

QuarterDateEPS actualEPS estEPS surpriseRevenue surprise
2026Q130.4.2026-0,71-0,86+17.1%+17.1%Beat
2025Q430.1.2026-0,98-0,77-27.1%-27.1%Miss
2025Q330.10.2025-0,94-0,78-20.3%-20.3%Miss
2025Q230.7.2025-0,95-0,80-19.1%-19.1%Miss